Unknown PHASE4 INTERVENTIONAL 2-arm NCT02591225

Left Atrial Thrombus Reduction - Effect of Dabigatran Versus Phenprocoumon

Phenprocoumon Versus Dabigatran in Subjects With Atrial Fibrillation and Left Atrial Thrombus - a Prospective, Randomized, Controlled, Open-label One Year Follow-up Pilot Study

Sponsor: Boehringer Ingelheim

Conditions Atrial Fibrillation Left Atrial Thrombosis

Interventions Dabigatranetexilate Phenprocoumon

Updated 6 times since 2017 Last updated: Nov 12, 2015 Started: Oct 31, 2015 Primary completion: Dec 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02591225, this PHASE4 trial focuses on Atrial Fibrillation and Left Atrial Thrombosis and remains ongoing. Sponsored by Boehringer Ingelheim, it has been updated 6 times since 2015, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4
Feb 2018 — Jun 2018 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status

▶ Show 1 earlier version

Jan 2017 — Feb 2018 [monthly]

Recruiting PHASE4

First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim
University of Ulm

Data source: University of Ulm

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ulm, Germany